Perspective Therapeutics (NYSE:CATX) Upgraded by Cantor Fitzgerald to “Strong-Buy” Rating

Perspective Therapeutics (NYSE:CATX) was upgraded by equities researchers at Cantor Fitzgerald to a “strong-buy” rating in a research report issued on Wednesday,Zacks.com reports.

Several other equities analysts also recently issued reports on the stock. Wedbush reissued an “outperform” rating and set a $11.00 price target on shares of Perspective Therapeutics in a report on Friday, January 24th. UBS Group started coverage on shares of Perspective Therapeutics in a research note on Thursday, October 24th. They issued a “buy” rating and a $20.00 price target on the stock. Bank of America cut Perspective Therapeutics from a “buy” rating to a “neutral” rating and cut their price target for the company from $24.00 to $5.00 in a report on Monday, November 25th. Oppenheimer decreased their price objective on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a report on Friday, November 22nd. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $16.00 price target on shares of Perspective Therapeutics in a research report on Tuesday, January 14th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Perspective Therapeutics currently has an average rating of “Buy” and a consensus price target of $15.14.

Perspective Therapeutics Price Performance

Shares of Perspective Therapeutics stock opened at $3.54 on Wednesday. The business has a 50-day moving average price of $3.50 and a 200 day moving average price of $9.30. Perspective Therapeutics has a fifty-two week low of $2.70 and a fifty-two week high of $19.05.

Perspective Therapeutics (NYSE:CATX) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.21). The business had revenue of $0.37 million during the quarter. Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. On average, equities analysts forecast that Perspective Therapeutics will post -0.88 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Johan M. Spoor acquired 14,500 shares of the stock in a transaction dated Monday, November 25th. The shares were acquired at an average cost of $3.78 per share, for a total transaction of $54,810.00. Following the completion of the transaction, the chief executive officer now owns 152,072 shares in the company, valued at approximately $574,832.16. This trade represents a 10.54 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Heidi Henson purchased 25,975 shares of the company’s stock in a transaction that occurred on Wednesday, December 4th. The stock was acquired at an average cost of $3.85 per share, with a total value of $100,003.75. Following the transaction, the director now directly owns 25,975 shares of the company’s stock, valued at approximately $100,003.75. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased 67,570 shares of company stock valued at $256,789 over the last 90 days. 3.52% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. The Manufacturers Life Insurance Company boosted its position in Perspective Therapeutics by 8.9% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 20,514 shares of the company’s stock valued at $274,000 after buying an additional 1,672 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Perspective Therapeutics by 5.8% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 58,678 shares of the company’s stock valued at $783,000 after acquiring an additional 3,211 shares during the last quarter. US Bancorp DE increased its position in Perspective Therapeutics by 142.7% in the third quarter. US Bancorp DE now owns 6,576 shares of the company’s stock worth $88,000 after purchasing an additional 3,866 shares during the period. Rhumbline Advisers raised its holdings in Perspective Therapeutics by 4.5% during the 4th quarter. Rhumbline Advisers now owns 94,992 shares of the company’s stock worth $303,000 after purchasing an additional 4,075 shares during the last quarter. Finally, nVerses Capital LLC acquired a new position in Perspective Therapeutics during the 3rd quarter valued at about $57,000. 54.66% of the stock is owned by institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.